Key result
Statin use is linked to ~78% lower 28-day mortality in Klebsiella pneumoniae bloodstream infections.
Why the study?
Patients with Klebsiella pneumoniae bloodstream infection have a high risk of death and septic shock, and risk factors for mortality and severity need identification.
Does statin use reduce 28-day mortality in patients with Klebsiella pneumoniae bloodstream infection?
Observational (n=279)
Does statin use reduce 28-day mortality in patients with Klebsiella pneumoniae bloodstream infection?
Statin use is associated with a significantly reduced risk of 28-day mortality in patients with Klebsiella pneumoniae bloodstream infection.
Answers are grounded in this paper and cite their sources.
Statin use was associated with lower 28-day mortality in K. pneumoniae BSI; hypothesis-generating and requires RCT confirmation before practice change.
Background: (BSI-KP) have a high risk of death and septic shock. This study aims to identify the risk factors for mortality and severity in patients of BSI-KP. Methods: in blood were included in this study. The risk factors of 28-day mortality and septic shock in BSI-KP patients were analyzed, respectively. Results: A total of 279 patients enrolled and the all-cause 28-day mortality rate was 11.8%. The use of statins (OR 0.220, 95% CI 0.060-0.801, p = 0.022) and quinolones (OR 0.356, 95% CI 0.143-0.887, p = 0.027) were both independent protective factors for death within 28 days, while the use of vasoactive drugs (OR 7.377, 95% CI 1.775-30.651, p = 0.006) was a risk factor. Besides, pulmonary disease (OR 2.348, 95% CI 1.126-4.897, p = 0.023), bleeding and coagulation disorders (OR 3.626, 95% CI 1.783-7.372, p < 0.001), respiratory failure (OR 2.823, 95% CI 0.178-6.767, p = 0.020) and kidney dysfunction (OR 2.450, 95% CI 1.189-5.047, p = 0.015) were independent risk factors for patients suffered from septic shock while hypertension was a protective one. The receiver operating characteristic (ROC) curves could well predict the risk of death within 28-day (area under ROC = 0.855, 95% CI = 0.796-0.914, p < 0.001) and septic shock (AUROC = 0.815, 95% CI = 0.755-0.874, p < 0.001) in patients with BSI-KP. Conclusion: The use of statins could decrease the risk of 28-day mortality in patients of BSI-KP. The risk factor-based prediction model provided evidence for drug treatment in BSI-KP patients. Paying more attention to the strategy of drug treatment will be an optimal way to improve patient's outcome in clinical practice.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) conducted an observational in Klebsiella pneumoniae bloodstream infection (BSI-KP) (n=279). Statins vs. Non-use of statins was evaluated on 28-day mortality (OR 0.220, 95% CI 0.060-0.801, p=0.022). Statin use was an independent protective factor for 28-day mortality in patients with Klebsiella pneumoniae bloodstream infection.
Synapse has enriched 10 related papers. Consider them for comparative context: